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Purpose: This study is aimed at identifying the anti-inflammatory mechanisms of a methanol extract of 
Polyopes lancifolius (MEPL) in lipopolysaccharide (LPS)-stimulated BV2 microglia cells. 
Methods: The expression of mRNA and protein were investigated RT-PCR and western blot analyses 
in LPS-stimulated BV2 microglial cells. The level of nitric oxide (NO) production was analyzed using 
Griess reaction. The release of prostaglandin E2 (PGE2) and tumor necrosis factor-α (TNF-α) were 
determined using sandwich ELISA. NF-κB activation was detected using EMSA methods. 
Results: MEPL significantly suppressed NO production in LPS-stimulated BV2 cells without any 
cytotoxicity. The results also indicate that MEPL decreased the production of PGE2 and TNF-α in LPS-
stimulated BV2 cells. Furthermore, pretreatment with MEPL resulted in a downregulation of LPS-
induced mRNA and protein expression of inducible NO synthase (iNOS), cyclooxygenase-2 (COX-2) 
and TNF-α. Investigation of the effect of MEPL on nuclear factor-κB (NF-κB) activity, which is a potential 
transcriptional factor for regulating inflammatory genes such as iNOS, COX-2 and TNF-α, showed that 
MEPL substantially inhibited the LPS-induced DNA-binding activity of NF-κB. MEPL also suppressed 
the LPS-induced degradation and phosphorylation of IκBα, and it consequently blocked p65 
translocation from the cytosol to the nucleus.  
Conclusion: These data show that MEPL may regulate LPS-induced NO, PGE2, and TNF-α production 
by suppressing NF-κB activity. 
 
Keywords: Polyopes lancifolius, Nitric oxide, Prostaglandin E2, Tumor necrosis factor-α, Nuclear factor-
κB 
 
Received: 1 April 2011       Revised accepted: 11 December 2011 
 
 
*Corresponding author:  Email: immunkim@jejunu.ac.kr; Tel: +82 64 754 3427; Fax: +82 64 756 3493
Jayasooriya et al 
Trop J Pharm Res, February 2012;11 (1): 44 
INTRODUCTION 
 
Inflammation is an important host response to 
external challenge or cellular injury, which is 
mediated by a variety of cell signaling 
pathways to balance the restoration of tissue 
structure and function [1]. As a result of the 
activation of these signaling pathways, many 
genes are expressed that produce different 
kinds of mediators such as nitric oxide (NO) 
and prostaglandins, which are generated by 
inducible isoforms of NO synthase (iNOS) 
and cyclooxygenase-2 (COX-2), respectively 
and cytokines such as tumor necrosis factor-
α (TNF-α) [2]. According to recent studies, 
excessive and abnormal production of these 
mediators results in severe tissue damage, 
systemic inflammatory syndrome, septic 
shock, and atherosclerosis [3]. Therefore, 
many researchers have recently attempted to 
identify some food sources and chemicals to 
suppress the aberrant expression of 
inflammatory mediators. 
 
Several well-characterized cell signaling 
pathways involve the production of different 
cytokines and inflammatory mediators. In 
particular, the nuclear factor-κB (NF-κB) 
pathway may play a key role due to its rapid 
activation and potency as a transcriptional 
activator [4]. NF-κB regulates several 
important processes such as cell growth, 
cancer, apoptosis, inflammation, immune 
responses, and developmental processes [5]. 
NF-κB is primarily regulated by its association 
with inhibitor κB (IκB) proteins in the 
cytoplasm. NF-κB normally exists in the 
cytoplasm in an inactive complex bound to 
IκB [6]. Most agents that activate NF-κB act 
through a common pathway based on 
phosphorylation-induced and/or proteasome-
mediated degradation of IκB [7]. Removal of 
the inhibitor can initiate nuclear localization 
signals on NF-κB subunits. Free NF-κB 
translocates to the nucleus where it binds to 
target DNA elements and activates the 
transcription of genes encoding proteins 
involved in immune responses, inflammation, 
or cell proliferation [8]. Therefore, many NF-
κB inhibitors, like non-steroidal anti-
inflammatory drugs, cell-permeable peptides 
such as SN-50, and proteasome inhibitors, 
have been thought as chemotherapeutic 
agents, because they suppress a variety of 
inflammatory diseases [9]. 
 
Many seaweed extracts are well-known as 
regulators of immune and inflammatory 
responses [10]. Therefore, many researchers 
are looking for more potent compounds with 
anti-inflammatory characteristics. Polyopes 
lancifolius, mainly found in the Republic of 
Korea and Japan, is such a seaweed with 
medicinal value [11]. Only one study has 
been conducted and this revealed that 
bromophenol purified from P. lancifolia, which 
was thought to be the same species as P. 
lancifolius, may have potential as a natural 
nutraceutical for treating type 2 diabetes [11]. 
Nevertheless, little evidence exists regarding 
the anti-inflammatory properties of this 
seaweed. 
 
In this study, we investigated the effects of a 
methanol extract of P. lancifolius (MEPL) on 
the expression of NO, PGE2, and TNF-α in 
lipopolysaccharide (LPS)-stimulated BV2 
microglia cells. Our data showed that MEPL 
downregulated iNOS, COX-2, and TNF-α 
mRNA expression in LPS-stimulated BV2 
cells. MEPL also inhibited LPS-induced NF-
κB activation by suppressing the degradation 
and phosphorylation of IκBα in the cytoplasm 




Preparation of MEPL 
 
MEPL was purchased from Jeju HI-Tech 
Industry Development Institute (extract NO. 
1340; Jeju, Republic of Korea). The red alga, 
P. lancifolius (stock NO. AR038) was 
collected along the Jeju Island coast of 
Republic of Korea in April, 2005. Briefly, fresh 
P. lancifolius was washed three times with 
tap water to remove salt, epiphyte, and sand 
on the surface of the samples before storage 
at -20 ºC. The frozen samples were 
lyophilized and homogenized using a grinder 
before extraction. The dried powder was 
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Lipopolysaccharide (LPS) and 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium 
bromide (MTT) were purchased from Sigma 
Chemical Co., St. Louis, MO, USA. 
Dulbecco’s modified Eagle’s medium 
(DMEM) and fetal bovine serum (FBS) were 
obtained from WelGENE Inc., Daegu, 
Republic of Korea. Antibodies against iNOS, 
COX-2, p65, IκBα and phospho (p)-IκBα 
polyclonal antibodies were purchased from 
Santa Cruz Biotechnology, Santa Cruz, CA, 
USA. The antibody against β-actin was from 
Sigma. Peroxidase-labeled goat anti-rabbit 
immunoglobulin was purchased from KOMA 
Biotechnology, Seoul, Republic of Korea. 
Other chemicals were purchased as Sigma 
grade. 
 
Cell culture and sample treatment 
 
BV2 cell lines were cultured at 37 
o
C in 5 % 
CO2 in DMEM supplemented with 10% FBS 
and antibiotics. For the analysis of cell 
viability, the cells (1 × 10
5
 cells/ml) were 
incubated with the various concentrations of 
MEPL 1 h before stimulation with LPS (1.0 
µg/ml) for the indicated time. 
 
Analysis of cell viability 
 
Cell viability was determined by an MTT 
assay. BV2 cells (1 × 10
5
 cells/ml) were 
plated on 24-well plates and incubated 
overnight. The cells were pretreated with 
varying concentrations of MEPL (50, 75, 100, 
150, 200 µg/ml) for 1 h and then stimulated 
with LPS (1.0 µg/ml) for 24 h. MTT assay was 
used to determine cell viability. 
 
Nitric oxide determination 
 
BV2 cells (1 × 10
5
 cells/ml) were plated onto 
24-well plates and pretreated with the 
indicated concentrations of MEPL 1 h before 
treatment with LPS (1.0 µg/ml) for 24 h. 
Supernatants were collected and assayed for 
NO production using Griess reagent. Nitrite 
concentration was determined using a 
dilution of sodium nitrite as a standard. 
 
Measurement of PGE2 and TNF-α 
 
Expression levels of PGE2 and TNF-α were 
measured using enzyme linked 
immunosorbent assay (ELISA) kit (R&D 
Systems, Minneapolis, MN, USA) according 
to the manufacturer’s instructions. 
 
Isolation of total RNA and RT-PCR 
 
Total RNA was extracted using easy-BLUE
TM
 
total RNA extraction kit (Invitrogen, Carlsbad, 
CA, USA) according to the manufacturer’s 
instruction. Two microgram RNA was 
reverse-transcribed using MMLV reverse 
transcriptase (Promega, Madison, WI, USA). 
cDNA was amplified by PCR using specific 
primer iNOS (forward 5’-cct cct cca ccc tac 
caa gt-3’ and reverse 5’-cac cca aag tgc ttc 
agt ca-3’), COX-2 (forward 5’-aag act tgc cag 
gct gaa ct-3’ and reverse 5’-ctt ctg cag tcc 
agg ttc aa-3’), TNF-α (forward 5’-gcg acg tgg 
aac tgg cag aa-3’ and reverse 5’-tcc atg ccg 
ttg gcc agg ag-3’), and β-actin (forward 5’-tgt 
gat ggt ggg aay ggg tc-3’ and reverse 5’-ttt 
gat gtc acg cac gat tt-3’). The following PCR 
conditions were applied: COX-2 and iNOS, 
25 cycles of denaturation at 94 °C for 30 s, 
annealing at 59 °C for 30 s, and extended at 
72 °C for 30 s; β-actin, 23 cycles of 
denaturation at 94 °C for 30 s, annealing at 
57 °C for 30 s, and extended at 72 °C for 30 
s. β-actin was used as an internal control to 
evaluate relative expression of iNOS, COX-2, 
and TNF-α. 
 
Western blot analysis 
 
Total cell extracts were prepared using PRO-
PREP protein extraction kit (iNtRON 
Biotechnology; Sungnam, Republic of Korea). 
The preparation of cytoplasmic and nuclear 
extracts was conducted using NE-PER 
nuclear and cytosolic extraction reagents 
(Pierce, Rockford, IL, USA). Total cell 
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extracts were separated on polyacrylamide 
gels and then standard procedures were 
used to transfer them to the nitrocellulose 
membranes. The membranes were 
developed using an ECL reagent 
(Amersham, Arlington Heights, IL, USA). 
 
Electrophoretic mobility assay (EMSA) 
 
DNA-protein binding assays were carried out 
with nuclear extract. Synthetic 
complementary NF-κB binding 
oligonucleotides (5’-AGT TGA GGG GAC 
TTT CCC AGG C-3’, Santa Cruz 
Biotechnology) were 3’-biotinylated using the 
biotin 3’-end DNA labeling kit (Pierce) 
according to the manufacturer’s instructions. 
Assays were performed using a Lightshift 
EMSA Optimization kit (Pierce) according to 




All data were derived from at least three 
independent experiments. The images were 
visualized with Chemi-Smart 2000 (Vilber 
Lourmat, Marine; Cedex, France). Images 
were captured using Chemi-Capt (Vilber 
Lourmat) and transported into Photoshop. All 
bands were quantified by Scion Imaging 
software (http://www.scioncorp.com). 
Statistical analyses were conducted using 
SigmaPlot software (version 11.0). Values 
were presented as mean ± SE. Significant 
differences between the groups were 
determined using two-way ANOVA test. 




Effect of MEPL on cell viability 
 
To determine the effect of MEPL on BV2 
cells, an MTT assay was performed at 24 h 
after treatment with MEPL (50 – 200 µg/ml) in 
the presence or absence of LPS. MEPL (50 – 
150 µg/ml) had no cytotoxic effect on BV2 
cells. However, cell viability was reduced 
when 200 µg/ml of MEPL was used with LPS. 
MEPL as well as LPS (1 µg/ml) alone did not 
show any cytotoxic effect on BV2 cells (Fig 
1). Therefore, 50–100 µg/ml MEPL was 
applied in subsequent experiments. 
 
 
Fig 1: Effect of MEPL on BV2 cell viability. Cells 
(1 × 10
5
 cells/ml) were incubated with the 
indicated concentrations of MEPL (50 – 200 µg/ml) 
for 1 h before lipopolysaccharide (1.0 µg/ml) 
treatment for 24 h; n = 3; *p < 0.05 compared with 
untreated control. 
 
Effect of MEPL on LPS-induced NO and 
PGE2 production  
 
Cells were stimulated with LPS (1.0 µg/ml) for 
24 h after pretreatment with MEPL (100 
µg/ml) for 1 h. NO and PGE2 production were 
analyzed using the Griess reaction assay and 
ELISA, respectively. Stimulating the cells with 
LPS resulted in a significant increase in NO 
production (19.3 ± 0.7 µM) compared to the 
untreated control (5.1 ± 0.2 µM; Fig 2A). 
Importantly, MEPL treatment significantly 
inhibited LPS-induced NO production to the 
level of the untreated control (5.1 ± 0.2 µM). 
Consistent with the inhibition of NO 
production, MEPL treatment (134 ± 11 pg/ml) 
markedly attenuated LPS-induced PGE2 
production (465 ± 35 pg/ml; Fig 2B). Our data 
also revealed that MEPL alone (83 ± 19 
pg/ml) sustained PGE2 production compared 
to the untreated control (80 ± 21 pg/ml). 
Taken together, these results indicate that 
MEPL significantly suppressed the release of 
NO and PGE2 in LPS-stimulated BV2 cells. 
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Fig 2: Effect of MEPL on LPS-induced nitric oxide 
(NO) (A) and prostaglandin (PG) E2 (B) production 
in BV2 cells. Cells (1 × 10
5
 cells/ml) were 
incubated with 100 µg/ml of MEPL for 1 h before 
LPS (1.0 µg/ml) treatment for 24 h; n = 3; *p < 
0.05 compared with the value in cells treated with 
LPS alone. 
 
Effect of MEPL on LPS-induced iNOS and 
COX-2 protein and mRNA 
 
To assess whether MEPL regulates NO and 
PGE2 production at the transcriptional level, 
iNOS and COX-2 protein and mRNA 
expression were determined by Western blot 
and RT-PCR analyses, respectively. 
Although iNOS and COX-2 protein 
expression increased significantly in the 
presence of LPS alone, Western blot analysis 
data showed decreasing iNOS and COX-2 
protein expression following the MEPL 
pretreatment (Fig 3A). We further 
investigated these results by conducting an 
RT-PCR analysis for iNOS and COX-2 
mRNA expression. The RT-PCR analysis 
showed that LPS treatment alone significantly 
increased iNOS and COX-2 expression at the 
transcriptional level at 6 h (Fig 3B). But these 
expressions were downregulated after 
pretreatment with MEPL at 100 µg/ml, similar 
to the western blot analysis data. Taken 
together, these data indicate that MEPL 
suppressed the upregulation of LPS-
stimulated iNOS and COX-2 expression at 
the transcriptional level. 
 
Fig 3: Effect of MEPL on LPS-induced iNOS and 
COX-2 protein (A) and mRNA (B) expression in 
BV2 cells. Cells (1 × 10
5
 cells/ml) were incubated 
with MEPL (100 µg/ml) 1 h before LPS (1.0 µg/ml) 
treatment for 6 h; n = 3. 
 
Effect of MEPL on LPS-induced TNF-α 
production and mRNA expression 
 
Next, we investigated TNF-α and TNF-α 
mRNA production in LPS-induced BV2 cells. 
Cells were pretreated with MEPL (100 µg/ml) 
for 1 h before LPS stimulation for 24 h, and 
the level of TNF-α in the culture supernatant 
was determined by ELISA. Consistent with 
the NO and PGE2 data, treating the cells with 
LPS alone significantly increased TNF-α 
production approximately 10-fold (3533 ± 65 
pg/ml) compared to the untreated control 
(332 ± 39 pg/ml); however, the LPS-induced 
TNF-α increase was restored to a 50% 
reduction in the presence of MEPL (1540 ± 
35 pg/ml; Fig 4A). To determine the effect of 
MEPL on TNF-α gene expression, an RT-
PCR analysis was performed at 6 h after LPS 
treatment. The RT-PCR data showed that 
MEPL suppressed TNF-α mRNA expression 
in LPS-stimulated BV2 cells (Fig 4B). These 
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data indicate that MEPL regulates TNF-α 
production in LPS-stimulated BV2 microglia 
cells by regulating TNF-α gene expression. 
 
 
Fig 4: Effect of MEPL on LPS-induced TNF-α 
production (A) and TNF-α mRNA expression (B) in 
BV2 cells. Cells (1 × 10
5
 cells/ml) were incubated 
with 100 µg/ml MEPL for 1 h before LPS (1.0 
µg/ml) treatment for the indicated time; n = 3; *p < 
0.05 compared with the value in cells treated with 
LPS alone. 
 
Inhibitory effect of MEPL in LPS-induced 
NF-κB activity 
 
Activating NF-κB induces the expression of 
pro-inflammatory mediators such as iNOS, 
COX-2 and TNF-α [5]. Therefore, we used 
Western blot analysis and an electrophoretic 
mobility shift assay (EMSA) to investigate 
how MEPL regulates the specific DNA-
binding activity of NF-κB. BV2 cells were 
preincubated with MEPL for 1 h and then 
stimulated with LPS for 30 min. The EMSA 
was conducted to determine whether MEPL 
inhibits the DNA-binding activity of NF-κB. 
LPS caused a remarkable increase in binding 
complexes between NF-κB and specific-
binding DNA; however, pretreatment with 
MEPL significantly reduced LPS-induced NF-
κB binding activity (Fig 5A). In a parallel 
experiment, LPS significantly induced the 
phosphorylation and degradation of IκBα and 
increased p65 expression in the nuclear 
compartment of BV2 cells (Fig 5B). However, 
nuclear translocation of p65, and 
phosphorylation and degradation of IκBα 
induced by LPS were inhibited in cells 
preincubated with MEPL (Fig 5B). 
Furthermore, N-acetyl-L-cysteine (NAC) was 
used as a potent proteasome and proteases 
inhibitor of Rel/NF-KB activity to confirm 
those results. We conducted an RT-PCR 
analysis to detect iNOS, COX-2, and TNF-α 
mRNA expression in the presence of NAC. 
Interestingly, NAC inhibited the expression of 
LPS-stimulated iNOS, COX-2, and TNF-α 
expression at the transcriptional level (Fig 
5C). These data indicate that MEPL reduced 
NF-κB activity in LPS-stimulated BV2 cells by 




Fig 5: Effect of MEPL on NF-κB DNA binding 
activity in LPS-stimulated BV2 cells. Cells were 
pre-incubated with MEPL (100 µg/ml) for 1 h 
before stimulation with LPS (1.0 µg/ml) for 30 min. 




Inhibitors of inflammatory mediators and 
cytokines have been considered an approach 
to anti-inflammatory drugs. Our data revealed 
that MEPL inhibited LPS-induced NO and 
PGE2 production by suppressing iNOS and 
COX-2 mRNA expression in BV2 cells 
without cytotoxicity. MEPL also decreased 
TNF-α production by suppressing its mRNA 
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expression. Furthermore, we showed that 
these effects occurred by inhibiting NF-κB 
activity. These data indicate that MEPL 
alleviates pro-inflammatory mediators such 
as NO, PGE2, and TNF-α via suppression of 
NF-κB activity. 
 
Expression of NO, PGE2, and TNF-α plays a 
critical role in macrophage activation and is 
also associated with acute and chronic 
inflammatory diseases [12]. Particularly, NO 
normally contributes to the control of 
replication or killing of intracellular microbial 
pathogens and cancer cells [13]. However, its 
uncontrolled release can result in 
inflammatory destruction of target tissues 
during an infection [14]. The release of iNOS-
mediated NO is one of the major factors 
during inflammatory processes. PGE2 is 
another pro-inflammatory mediator involved 
in inflammatory responses, which is 
generated by metabolism of arachidonic acid 
by cyclooxygenase (COX) [15]. Activation of 
the COX-2 gene is particularly responsible for 
various inflammatory diseases by inducing 
PGE2 overexpression [2]. Accumulating 
evidence confirms COX-2 as a potential 
therapeutic target for treating inflammatory 
diseases [2]. Additionally, TNF-α is a 
pleiotropic inflammatory cytokine involved in 
systemic inflammatory diseases [16]. 
Overproduction of TNF-α switches on 
signaling pathways that change the cell 
functions of LPS-stimulated macrophages 
[17]. As TNF-α plays a role in several 
diseases, a substantial amount of research 
has been conducted concerning TNF-α 
blockers and anti-TNF-α therapies. Recently, 
anti-TNF-α therapy has been broadly 
introduced to treat various inflammatory 
diseases [16]. Therefore, suppressing NO, 
PGE2, and TNF-α production by inhibiting 
their regulatory genes could be a very 
important therapeutic target for developing 
anti-inflammatory agents. Our results showed 
that MEPL attenuated the production of the 
anti-inflammatory mediators such as NO, 
PGE2, and TNF-α in LPS-induced BV2 cells. 
These data suggest the possibility of 
developing anti-inflammatory chemicals using 
MEPL. Nevertheless, further study is needed 
to elucidate what MEPL component 
suppresses the expression of anti-
inflammatory mediators. 
 
NF-κB has often been referred to as a central 
mediator and is strongly implicated in a 
variety of inflammatory diseases [9]. Many 
stimulants including LPS, bacteria, and 
viruses can lead to NF-κB activation, which 
leads to the control of the expression of many 
inflammatory cytokines, chemokines, immune 
receptors, and cell surface adhesion 
molecules [18]. Once NF-κB is fully activated, 
it participates in the regulation of various 
target genes in different cells and is involved 
in different functions [4]. In this study, we 
showed that MEPL inhibited p65 protein 
translocation via suppression of IκBα 
degradation. As a result, MEPL suppressed 
the LPS-induced DNA-binding activity of NF-
κB. Because the expression of many 
inflammatory genes, iNOS, COX-2, and TNF-
α are modulated by NF-κB binding to its 
specific promoter regions, it is a potential 
target for suppressing NF-κB activity and 
regulating LPS-induced inflammation [5]. We 
tested NF-KB activity with NAC, which is a 
proteasome and protease inhibitor of Rel/NF-
κB activity [19]. According to the RT-PCR 
analysis, iNOS, COX-2, and TNF-α mRNA 
expression was suppressed in the presence 
of NAC. Taken together, these results 
suggest that MEPL suppresses inflammatory 
mediators such as NO, PGE2, and TNF-α via 
LPS-induced NF-κB activity by suppressing 




This study showed that MEPL has anti-
inflammatory activity which depends on its 
ability to regulate NO, PGE2, and TNF-α 
production by suppressing NF-κB activation 
in LPS-stimulated BV2 microglia cells. The 
data suggest that MEPL has a high potential 
to treat LPS-induced inflammatory diseases. 
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